HHS Proposed Rule on Prescription Drug Safe Harbors

Ropes & Gray LLP

Ropes & Gray LLP

On January 31, 2019, the Office of Inspector General (“OIG”) of the U.S. Department of Health & Human Services (“HHS” or the “Department”) released a proposed rule that would narrow the existing regulatory discount safe harbor under the Anti-Kickback Statute (“AKS”) and create two new safe harbors. If finalized, the proposed rule would (i) exclude from the existing discount safe harbor discounts provided to Medicare Part D plans (including Medicare Advantage plans with a drug benefit), Medicaid managed care organizations (“MCOs”), and pharmacy benefit managers (“PBMs”); (ii) add a new safe harbor to protect certain discounts passed along to federal health care program beneficiaries; and (iii) add a new safe harbor to protect certain fees prescription drug manufacturers pay to PBMs. The stated purpose of the proposed rule is to update the discount safe harbor to address the modern prescription drug distribution model and protect federal health care programs and beneficiaries. Taken together, proposed changes do not directly affect the price-setting activities of pharmaceutical manufacturers, but instead appear designed to affect pharmaceutical prices indirectly by increasing transparency through requiring that any discounts be provided at the point of sale. At present, however, it is not clear what the ultimate effect of the proposed rule on beneficiary prescription drug costs will be. 

Amendments to the Discount Safe Harbor under the Proposed Rule, and Potential Legal Challenges

The AKS broadly prohibits the exchange of anything of value intended to induce or reward referrals for or purchases of items and services reimbursed by Federal health care programs. The AKS’s prohibition can include discounts or other reductions in price offered to buyers on such items or services. However, discounts are permitted if they comply with the regulatory safe harbor at 42 C.F.R. § 1001.952(h) (and, though OIG disagrees, arguably if they comply with the statutory exception for discounts at 42 U.S.C. § 1320a-7b(b)(3)(A) on which the safe harbor is based). While the regulatory discount safe harbor was intended to encourage price competition that would ultimately benefit the Medicare and Medicaid programs,1 the proposed rule suggests that the safe harbor has not translated into cost savings for federal health care programs when used in the modern prescription drug distribution model. 

In the preamble to the proposed rule, OIG notes that rebate arrangements in the prescription drug supply chain may create incentives for manufacturers to keep list prices (and rebates) high, in order to gain preferred status from PBMs and health plans. Often, a portion of PBM compensation is derived from the difference between the list price and the price actually paid after accounting for rebates (the “net price”). Thus, an incentive exists for PBMs and health plans (which generally share the value of rebates) to encourage the use of drugs with higher list prices and rebates, typically by preferred formulary placement, because of the higher fees such drugs generate. A manufacturer that lowered list prices would reduce the difference between the list price and the net price, thereby lowering PBM and health plan fees, potentially causing the drug to be removed from the formulary or placed in a less-preferred tier. OIG argues that these incentives to keep list prices high result in higher out-of-pocket costs for beneficiaries and do not translate into lower federal health care spending per beneficiary.

The proposed rule narrows the existing regulatory discount safe harbor by excluding from protection discounts on prescription pharmaceuticals offered to Medicare Part D plans (including Medicare Advantage plans with a drug benefit), Medicaid MCOs, and PBMs dealing on behalf of such entities. More specifically, the proposed rule amends the definition of “discount” provided at 42 C.F.R. § 1001.952(h) by carving out “reduction[s] in price or other remuneration from a manufacturer in connection with the sale or purchase of a prescription pharmaceutical product” to Medicare and Medicaid plans and PBMs. Notably, the proposed rule would not affect discounts provided to entities other than plan sponsors and PBMs (such as hospitals, clinics, physician practices, pharmacies, or wholesalers); nor would it alter supplemental rebates between states and drug manufacturers. Additionally, although the proposed rule would not directly affect discounts offered to commercial plans, HHS noted in its commentary to the proposed rule that, consistent with OIG’s historic concern regarding the “pull-through” effect of remuneration provided for services payable by non-Federal health care payors, continued rebates in the commercial insurance market also could be subject to scrutiny under the AKS. The “pull-through” concern here is driven by a fear on the part of OIG that that private pay-only rebates are intended to induce purchases of federal government program reimbursable drugs (for example, private pay rebates are provided in exchange for favorable formulary treatment of Medicare/Medicaid-covered drugs). 

In support of its authority to issue the proposed rule, OIG points to Section 14 of the Medicare and Medicaid Patient and Program Protection Act of 1987, which tasks the Secretary of Health and Human Services (the “Secretary”) with creating new AKS safe harbors through rulemaking. Insurers, PBMs, and others might mount a legal challenge by arguing that the protected status of rebate arrangements cannot change without action by Congress because the statutory exception under which the regulatory discount safe harbor is based protects “a discount or other reduction in price obtained by a provider of services or other entity under a Federal health care program” (emphasis added). It is difficult to see how MCOs that contract with Medicare or Medicaid do not satisfy this definition. PBMs likely would argue that when they act on behalf of Medicaid MCOs and Medicare Part D sponsors, they should be considered an “other entity” under the statute and thus within the ambit of the exception created by Congress, which the Secretary cannot unilaterally change through notice-and-comment rulemaking. 

New Proposed Safe Harbor: Point of Sale (“POS”) Drug Price Reductions

The proposed rule introduces a new safe harbor that would protect a new form of reduction in price on prescription drugs offered to Medicare Part D plans, Medicaid MCOs, or PBMs acting on behalf of either. In order to qualify for protection, drug price reductions would need to satisfy the following conditions:

  1. The price reduction must be set in advance with the plan sponsor. The proposed rule provides that “set in advance” means fixed and disclosed in writing by the time of the initial purchase. Initial purchase means the first purchase of the product at the reduced price by the Medicare Part D plan sponsor or Medicaid MCO on behalf of the enrollee. Like the current discount safe harbor, this proposed safe harbor would exclude price reductions offered to one payor, but not to Medicare or Medicaid.
  2. Rebates must take effect through chargebacks or be required by law. The proposed definition of “chargeback” is a payment that a manufacturer makes directly or indirectly to a dispensing pharmacy such that the total payment to the pharmacy is at least equal to the price agreed upon in writing between the manufacturer and the Medicare Part D plan sponsor, Medicaid MCO, or PBM. 
  3. The POS price charged by a pharmacy to a beneficiary must completely reflect the price reduction, even if the pharmacy only later receives the chargeback. As currently drafted, it is unclear how this provision will affect a beneficiary’s cost-sharing obligation. The proposed rule’s preamble suggests that the beneficiary’s cost-sharing obligation should be calculated based on a reduced price, such as a coinsurance calculated as a percentage of the standard plan reimbursement amount minus the manufacturer rebate. However, the text of the proposed rule requires that the reduction in price be applied to the price “charged to the beneficiary at the point of sale” and thus could be read to require elimination of the beneficiary’s cost-sharing obligation, since that is the amount charged to the beneficiary at the point of sale. It is not clear what happens to the “excess” if the amount of the chargeback exceeds the beneficiary’s cost-sharing obligation.

These requirements are intended to exclude from protection arrangements that resemble rebates, whether or not they are explicitly labeled as such. The safe harbor is satisfied only if all three of the conditions listed above are satisfied. Notably, a pharmaceutical manufacturer will not be able to ensure compliance with all three conditions since compliance with certain of the conditions is dependent on the actions of plans and third-party pharmacies that are downstream in the prescription drug distribution model. This is in contrast to the existing discount safe harbor, which enumerates different obligations for buyers, sellers, and offerors, recognizing the fact that different parties can control different portions of a discount arrangement. The proposed rule also does not address situations in which PBMs and pharmacies are related through ownership, and OIG has requested comments on how to address such scenarios. 

New Proposed Safe Harbor: PBM Service Fees

The proposed rule introduces a second new regulatory safe harbor that would protect fixed fees that a drug manufacturer pays to a PBM for services that the PBM provides to the manufacturer that relate to the PBM’s arrangements with any health plan. OIG envisions this safe harbor as providing additional fraud and abuse protection for services that PBMs provide to drug manufacturers, such as using health plan claims data to help manufacturers avoid duplicate discounts on claims for 340B drugs.2 The safe harbor would not protect services that the PBM furnishes to a health plan that are not for the benefit of the health plan rather than the manufacturer. In order to fall under the safe harbor, the fees would need to satisfy the following conditions:

  1. Written agreement. The PBM and the manufacturer must have a written agreement that (i) covers all of the PBM’s services for the manufacturer that relate to the PBM’s relationships with health plans and (ii) specifies each of the services that the PBM will provide and the compensation it will receive for providing them. 
  2. Proper terms for compensation. The PBM’s compensation must (i) be consistent with fair market value in an arm’s length transaction, (ii) be a fixed payment not based on a percentage of sales, and (iii) not be based on the volume or value of referrals or business generated between the parties or between the manufacturer and the PBM’s health plans for which payment may be made under a federal health care program. 
  3. Annual written disclosures. The PBM annually must disclose in writing to its contracted health plans the services it provides to each manufacturer related to services that the PBM provides to the health plan, and the associated costs for those services. PBMs also must provide this information, as well as information regarding fee arrangements with manufacturers, to the Secretary upon request.

* * *

If finalized as proposed, the rule would significantly transform prescription drug reimbursement by Medicare Part D and Medicaid MCOs. Although it is difficult to predict how manufacturers, PBMs, and health plans would react to the changes, OIG anticipates that enrollees’ out-of-pocket costs for prescriptions drugs would fall. Sicker enrollees who fill more prescriptions would therefore benefit most. However, the actuarial studies that the proposed rule cites indicate that premiums may rise as a result of narrowing the existing safe harbor, because the rebates as they currently stand under the discount safe harbor serve to lower premiums. Amending the discount safe harbor would reduce the rebates available, and thus may adversely affect federal health care program beneficiaries through increased premiums, as well as lead to increased federal spending.

Interested parties may submit comments by 5 P.M. eastern time on April 8, 2019.

1Medicare and State Health Care Programs: Fraud and Abuse; OIG Anti-Kickback, 56 Fed. Reg. 35,799, 35,953 (July 29, 1991) (codified at 42 C.F.R. pt. 1001).

2Section 340B of the Public Health Service Act imposes drug ceiling prices on covered outpatient drugs reimbursed by Medicaid.

Written by:

Ropes & Gray LLP

Ropes & Gray LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.